Inhibition of angiogenesis at endothelial cell level

Area of Science:

• Oncology
• Cell Biology
• Pharmacology

Background:

• Malignant tumors rely on angiogenesis, the formation of new blood vessels, for growth and metastasis.
• Endothelial cells, which form blood vessels, are accessible and genetically stable targets for anti-cancer drug development.
• Targeting endothelial cells can disrupt tumor vascularization and inhibit cancer progression.

Purpose of the Study:

• To review current therapeutic strategies targeting proliferating endothelial cells for cancer treatment.
• To provide an overview of clinically relevant basic mechanisms in endothelial cell-targeted therapies.
• To offer a new perspective on the development of anti-angiogenesis drugs.

Main Methods:

• Summary of different therapeutic approaches targeting endothelial cells.
• Review of ongoing clinical trials for anti-angiogenesis therapies.
• Analysis of key molecular mechanisms, including VEGF, ETS, and radionanotargeting.

Main Results:

• Several approaches targeting endothelial cells are currently in clinical trials.
• Understanding of endothelial cell biology reveals numerous potential drug targets.
• Inhibitors can be categorized based on their mechanism of action: blocking activators, direct inhibition, or signaling pathway interference.

Conclusions:

• Targeting endothelial cells represents a promising therapeutic strategy against malignant tumors.
• Further preclinical and clinical development is essential for advancing these therapies.
• Breakthroughs in applied therapies are anticipated in the near future.